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P
eople with diabetes are more likely
to be hospitalized and to have
longer durations of hospital stay
thanthosewithoutdiabetes.Arecentsur-
vey estimated that 22% of all hospital in-
patientdayswereincurredbypeoplewith
diabetes and that hospital inpatient care
accounted for half of the 174 billion USD
total U.S. medical expenditures for this
disease (1). These ﬁndings are due, in
part, to the continued expansion of the
worldwideepidemicoftype2diabetes.In
theU.S.alone,thereare1.6millionnew
cases of diabetes each year, with an over-
all prevalence of 23.6 million people
(7.8% of the population, with one-fourth
of the cases remaining undiagnosed). An
additional57millionAmericanadultsare
at high risk for type 2 diabetes (2). Al-
though the costs of illness-related stress
hyperglycemia are not known, they are
likely to be considerable in light of the
poor prognosis of such patients (3–6).
There is substantial observational ev-
idence linking hyperglycemia in hospital-
izedpatients(withorwithoutdiabetes)to
poor outcomes. Cohort studies as well as
a few early randomized controlled trials
(RCTs) have suggested that intensive
treatment of hyperglycemia improved
hospital outcomes (5–8). In 2004, this
evidence led the American College of En-
docrinology (ACE) and the American As-
sociation of Clinical Endocrinologists
(AACE), in collaboration with the Amer-
ican Diabetes Association (ADA) and
other medical organizations, to develop
recommendations for treatment of inpa-
tient hyperglycemia (9). In 2005, the
ADA added recommendations for treat-
ment of hyperglycemia in the hospital
to its annual Standards of Medical Care
(10). Recommendations from the ACE
andtheADAgenerallyendorsedtightgly-
cemic control in critical care units. For
patients in general medical and surgical
units, where RCT evidence regarding
treatment targets was lacking, glycemic
goals similar to those advised for outpa-
tientswereadvocated(9,10).In2006,the
ACE and the ADA partnered on a joint
“calltoaction”forinpatientglycemiccon-
trol, addressing a number of systematic
implementationbarriersinhospitals(11).
Theseeffortscontributedtoagrowingna-
tional movement viewing the manage-
ment of inpatient hyperglycemia as a
quality-of-care measure.
Althoughhyperglycemiaisassociated
with adverse patient outcomes, interven-
tiontonormalizeglycemiahasyieldedin-
consistent results. Indeed, recent trials in
critically ill patients have failed to show
a signiﬁcant improvement in mortality
with intensive glycemic control (12,13)
or have even shown increased mortality
risk (14). Moreover, these recent RCTs
have highlighted the risk of severe hypo-
glycemia resulting from such efforts (12–
17). These outcomes have contributed to
confusionregardingspeciﬁcglycemictar-
gets and the means for achieving them
in both critically ill and noncritically ill
patients.
Recognizing the importance of glyce-
mic control across the continuum of care,
the AACE and the ADA joined forces to
develop this updated consensus state-
ment on inpatient glycemic management.
The central goals were to identify reason-
able,achievable,andsafeglycemictargets
and to describe the protocols, proce-
dures, and system improvements needed
to facilitate their implementation. This
documentisaddressedtohealthcarepro-
fessionals, supporting staff, hospital ad-
ministrators, and other stakeholders
focused on improved management of hy-
perglycemia in inpatient settings. Con-
sensus panel members extensively
reviewed the most current literature and
considered the following questions:
1. Does improving glycemic control im-
prove clinical outcomes for inpatients
with hyperglycemia?
2. What glycemic targets can be rec-
ommended in different patient
populations?
3. What treatment options are available
for achieving optimal glycemic targets
safely and effectively in speciﬁc clini-
cal situations?
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glycemia represent a safety concern?
5. What systems need to be in place to
achieve these recommendations?
6. Is treatment of inpatient hyperglyce-
mia cost-effective?
7. What are the optimal strategies for
transition to outpatient care?
8. What are areas for future research?
QUESTION 1: DOES
IMPROVING GLYCEMIC
CONTROL IMPROVE
CLINICAL OUTCOMES FOR
INPATIENTS WITH
HYPERGLYCEMIA?— Hypergly-
cemia in hospitalized patients, irrespective
ofitscause,isunequivocallyassociatedwith
adverse outcomes (5,6,18–25). Hypergly-
cemia occurs in patients with known or
undiagnosed diabetes, or it occurs during
acute illness in those with previously nor-
mal glucose tolerance (termed “stress hy-
perglycemia”) (8,26).
Intervention directed at reducing
blood glucose (BG) levels has resulted in
improved outcomes in some, but not all,
studies (5,18–25). Several recent clinical
trialsincriticallyillpatientshavereported
no reduction in mortality from intensive
treatment targeting near-euglycemia ver-
sus conventional management targeting
BG180mg/dl(10.0mmol/l).Ofcon-
siderable concern are reports of harm,
with higher rates of severe hypoglycemia
and even increased mortality (14) result-
ing from intensive glycemic control (12–
14,16,27,28). This variability in results
may be attributable to several factors,
including differences in intravenous (IV)
insulin treatment protocols and their im-
plementation, glycemic targets, patient
populations, methods for glucose moni-
toring, and insulin adjustment (12,29).
Thefollowingsectionfocusesprimar-
ily on results of recent studies with an
RCT design that investigated patient out-
comes with protocols targeting near-
normalization of BG levels. Readers are
referred to a previous ACE position state-
ment (9), an ACE/ADA consensus state-
ment (11), and a technical review (8) for
details related to earlier studies support-
ing inpatient glycemic management.
Data derived from surgical and
medical intensive care units
Observational studies have documented
that hyperglycemia after cardiothoracic
surgical procedures is associated with
higher rates (approximately twofold) of
woundinfection(20,30).Interventionsto
reduce hyperglycemia in this setting with
IVinsulintherapydecreaseinfectionrates
(19,21,31) and cardiac-related mortality
(5,32),incomparisonwithhistoricalcon-
trol subjects.
The results of several RCTs con-
ducted in critically ill patients in medi-
cal and surgical intensive care units
(ICUs) are summarized in Table 1
(5,13,14,16,27,28,33–36).Intensivein-
sulin therapy targeting arterial glucose
levelsof80–110mg/dl(4.4–6.1mmol/l)
in a surgical ICU patient population re-
sultedinasigniﬁcantdecreaseinmorbid-
ity and mortality (5). However, imple-
mentation of the identical protocol in
1,200 medical ICU patients by the same
investigators in the same institution di-
minished morbidity but failed to reduce
mortality. A sixfold increase in severe hy-
poglycemic events (BG 40 mg/dl [2.2
mmol/l]) was observed in the intensively
treated group (18.7 vs. 3.1%), and hypo-
glycemia was identiﬁed as an indepen-
dent risk factor for mortality (16).
The Efﬁcacy of Volume Substitution
and Insulin Therapy in Severe Sepsis
(VISEP) study reported no decrease in
mortality and higher rates of severe hypo-
glycemiawithintensiveinsulintherapyin
patients with severe sepsis (17 vs. 4.1%;
P  0.001) (13). Hypoglycemia—BG
40 mg/dl (2.2 mmol/l)—was identi-
ﬁed as an independent risk factor for
mortality (relative risk, 2.2 at 28 days;
95% CI, 1.6 to 3.0) (Dr. Frank Brunk-
horst [Jena University Hospital, Jena,
Germany], personal communication).
Similarly, intensive glycemic control in a
mixed medical and surgical ICU resulted
in no decrease in morbidity or mortality,
while increasing the rate of hypoglycemia
ﬁvefold (28).
The largest study to date, Normogly-
cemia in Intensive Care Evaluation—
Survival Using Glucose Algorithm Regu-
lation (NICE-SUGAR), a multicenter,
multinational RCT, tested the effect of
tight glycemic control on outcomes
among6,104criticallyillparticipants,the
majority of whom (95%) required me-
chanical ventilation (14). The 90-day
mortality was signiﬁcantly higher in the
intensivelytreatedversustheconvention-
ally treated group (78 more deaths; 27.5
vs. 24.9%; P  0.02) in both surgical and
medical patients. Mortality from cardio-
vascular causes was more common in the
intensively treated group (76 more
deaths; 41.6 vs. 35.8%; P  0.02). Severe
hypoglycemia was also more common in
the intensively treated group (6.8 vs.
0.5%; P  0.001).
A recent meta-analysis of RCTs re-
ported comparisons between intensive
insulin therapy with glycemic targets of
72–126 mg/dl (4.0–7.0 mmol/l) (com-
monly, 80 to 110 mg/dl [4.4–6.1 mmol/
l]) and less intensive therapy with targets
of 150 to 220 mg/dl (8.3–12.2
mmol/l) (commonly, 180 to 200 mg/dl
[10.0–11.1 mmol/l]). Among 8,432 crit-
ically ill patients, there was no signiﬁ-
cant difference in mortality between in-
tensive therapy and control groups (21.6
vs. 23.3%, respectively) (12). A decrease
in septicemia and a ﬁvefold increase in
hypoglycemia (13.7 vs. 2.5%) were ob-
served. In a second meta-analysis (17)
including 13,567 critically ill patients, a
favorable effect of intensive therapy on
mortality was noted only in surgical ICU
patients (relative risk, 0.63; CI, 0.44 to
0.91). There was a sixfold increase in the
rate of occurrence of hypoglycemia with
useofintensivetherapyinallICUpatients
(17).
The higher rates of severe hypoglyce-
miaassociatedwithintensiveinsulinther-
apy(12–14,16,27,28)raisethepossibility
that serious adverse events in the sub-
group of patients experiencing hypogly-
cemia offset, at least in part, any beneﬁt
derived from strict glycemic control in
the much larger subgroup of patients
without hypoglycemic events (13,16).
Hypoglycemic events, however, have
beeninfrequentlylinkedtomortality;this
ﬁndingsuggeststhatseverehypoglycemia
may be a marker of more serious under-
lying disease (13,14,16).
Data derived from patients with
acute myocardial infarction
Although hyperglycemia is associated with
adverse outcomes after acute myocardial
infarction (AMI) (37–41), reduction of
glycemia per se, and not necessarily the
use of insulin, is associated with im-
proved outcomes (7). It remains unclear,
however, whether hyperglycemia is a
marker of underlying health status or is a
mediator of complications after AMI.
Noniatrogenic hypoglycemia has also
been associated with adverse outcomes
and is a predictor of higher mortality
(7,42,43).
Several studies have attempted to
reproduce the favorable outcomes ob-
servedwithearlyimplementationofinsu-
lin therapy reported in the ﬁrst Diabetes
and Insulin-Glucose Infusion in Acute
Myocardial Infarction (DIGAMI) trial (33).
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patients with AMI and diabetes, failed to
show a decrease in mortality with such
intervention (34). The Hyperglycemia In-
tensive Insulin Infusion in Infarction
(HI-5) study randomly assigned patients
withAMIto24-hinfusionsofinsulinplus
glucose for 24 h (BG goal 180 mg/dl
[10.0 mmol/l]) or usual care. There
were no signiﬁcant differences in mortality,
although there was a decreased incidence
of congestive heart failure and reinfarc-
tion at 3 months in the intensively treated
group(35).TheverylargeClinicalTrialof
Reviparin and Metabolic Modulation in
Acute Myocardial Infarction Treatment
Evaluation—Estudios Cardiologicos Latin
America (CREATE-ECLA), with 20,201
patients, tested the efﬁcacy of glucose-
insulin-potassium infusion in post-AMI
patientsandfoundnodecreaseinmortal-
ity(44).Afailuretoachieveaprespeciﬁed
glycemic target with intensive therapy
that differed from those in the control
groupmayhavecontributedtotheseneg-
ative results (34,44).
Data derived from other critically ill
patients
Several retrospective studies have exam-
inedtherelationshipbetweenglycemiaand
clinical outcomes in patients with extensive
burns, body trauma, or traumatic brain in-
jury or who have undergone surgical treat-
ment for cerebral aneurysms (45–53). In
patients with subarachnoid hemorrhage,
hyperglycemia was associated with im-
paired cognition and deﬁcits in gross neu-
rologic function at 3 months (52). Patients
without diabetes who had severe blunt in-
jury and hyperglycemia (BG 200 mg/dl
[11.1 mmol/l]) were found to have a 2.2-
fold higher rate of mortality than those
with admission glucose of 200 mg/dl
(11.1 mmol/l) (54). Similar ﬁndings have
been reported by some investigators
(55,56)butnotothers(57,58).InanRCT
of tight glycemic control in 97 patients
with severe traumatic brain injury (59),
no signiﬁcant differences were noted in
infections, 6-month mortality, or neuro-
logic outcomes. The rate of occurrence of
hypoglycemia was twofold higher with
use of intensive insulin therapy.
Data derived from patients
undergoing transplantation
Diabetes in patients after transplant pro-
ceduressharesmanysimilaritieswithtype2
diabetes and is strongly associated with
cardiovascular disease and cardiac death
(60). Fuji et al. (61). examined the effects
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riodsin112patientsundergoingstemcell
transplantation.Hyperglycemiawasasso-
ciated with risk of organ failure, grades
II–IV acute graft-versus-host disease, and
non–relapse-related mortality, but not
with infection or fever. A similar study in
382 patients reported that in those pa-
tients not treated with glucocorticoids
during neutropenia, each 10 mg/dl (0.6
mmol/l) increase in BG was associated
with a 1.15-fold increase in the odds ratio
for bacteremia (62). Hammer et al. (63)
analyzedBGlevelsamong1,175adultpa-
tients receiving allogeneic hematopoietic
celltransplants.Hyperglycemia,hypogly-
cemia, and glycemic variability all corre-
lated with non–relapse-related mortality
within 200 days after transplantation.
Data derived from studies on
intraoperative glycemic management
In a double-blind, placebo-controlled
RCT involving 82 adults, intraoperative
glucose-insulin-potassium infusion dur-
ing a coronary artery bypass grafting
procedure did not reduce myocardial
damage,mortality,orlengthofstay(LOS)
(64). In a study of 399 patients undergo-
ing cardiac surgical procedures, intensive
insulintherapy(targetBG,80–100mg/dl
[4.4–5.6 mmol/l]) intraoperatively re-
sulted in no difference in patient out-
comes; postoperatively, however, both
groups were treated to similar glycemic
targets (36).
Data derived from pediatric ICUs
Although outside the scope of this con-
sensus statement, it is worth noting that
hyperglycemia (without diabetes) is also
common among pediatric patients with
critical illness (65–70), and it correlates
with mortality (70). An international,
multicenter RCT, which tested the effect
of intensive glycemic control in very-low-
birth-weight neonates, found higher rates
ofseverehypoglycemiaandnosigniﬁcant
difference in mortality or morbidity (71).
Incontrast,anotherrandomizedtrialcon-
ducted among 700 critically ill infants
(n  317) and children (n  383) re-
ported decreases in mortality, inﬂamma-
torymarkers,andLOSwithuseofintensive
insulin therapy, despite a greater frequency
of severe hypoglycemia (25 vs. 5%) (72).
Hyperglycemia in hospitalized
medical and surgical patients in
non-ICU settings
NoRCTshaveexaminedtheeffectofinten-
sive glycemic control on outcomes in hos-
pitalized patients outside ICU settings.
Several observational studies, however,
pointtoastrongassociationbetweenhyper-
glycemia and poor clinical outcomes, in-
cluding prolonged hospital stay, infection,
disability after discharge from the hospital,
and death (4,7,35,73–81).
Several studies have found glucose
variabilitytobeanindependentpredictor
of mortality in critically ill patients
(63,66,82). Whether intervention to con-
trol glycemic variability, per se, improves
outcomes is not known (83).
Summary of clinical trials reviewed
for question 1
Overall, although a very tight glucose tar-
get (80–110 mg/dl [4.4–6.1 mmol/l])
wasbeneﬁcialinapredominantlysurgical
ICU population (5), this target has been
difﬁcult to achieve in subsequent studies,
including the recently published NICE-
SUGAR study (14), without increasing
the risk for severe hypoglycemia (12,
13,16,27,28). In addition, there has been
no consistent reduction in mortality with
intensivecontrolofglycemia(12,17),and
increased mortality was observed in the
largest published study to date (14). The
reasons for this inconsistency are not en-
tirely clear. The positive results reported
intheinitialstudiesmayhavebeenattrib-
utable to differences in measurement and
reporting of BG values, selection of par-
ticipants, glycemic variability, or nutri-
tional support (12,17,84). Nevertheless,
recent attempts to achieve tight glycemic
control either have not reduced or have
actually increased mortality in multi-
center trials and clearly led to higher rates
of hypoglycemia (13,14,16).
Despite the inconsistencies, it would
be a serious error to conclude that judi-
cious control of glycemia in critically ill
patients, and in non-ICU patients in gen-
eral, is not warranted. First, on the basis
of a large number of studies in a variety
of inpatient settings, uncontrolled hyper-
glycemia clearly is associated with poor
outcomes. Second, although severe hy-
poglycemic events are observed in an un-
acceptably high number of patients
receiving intensive insulin therapy with
protocolstargetingaBGof80–110mg/dl
(4.4–6.1mmol/l)(12),thisriskcanlikely
be minimized with relaxation of targets,
improvement and standardization of
protocols, and their careful implemen-
tation.Third,perhapsmajorbeneﬁcialef-
fects on outcomes can be derived from a
higher target range of glucose than 80–
110 mg/dl in comparison with uncon-
trolled hyperglycemia.
Finally, until further information be-
comes available, it is prudent to continue
to emphasize the importance of glycemic
control in hospitalized patients with crit-
icalandnoncriticalillnesswhileaimingat
targetsthatarelessstringentthan80–110
mg/dl (4.4–6.1 mmol/l), a topic that is
discussed in detail subsequently.
QUESTION 2: WHAT
GLYCEMIC TARGETS CAN
BE RECOMMENDED IN
DIFFERENT PATIENT
POPULATIONS?— The manage-
ment of hyperglycemia in the hospital
presents unique challenges that stem
from variations in a patient’s nutritional
status and level of consciousness, the
practical limitations of intermittent glyce-
mic monitoring, and the ultimate impor-
tance of patient safety. Accordingly,
reasonable glucose targets in the hospital
setting are modestly higher than may be
routinely advised for patients with diabe-
tes in the outpatient setting (85,86).
Deﬁnition of glucose abnormalities
Inthisreport,hyperglycemiaisdeﬁnedas
anyBGvalue140mg/dl(7.8mmol/l).
Levels that are signiﬁcantly and persis-
tently above this level may necessitate
treatment in hospitalized patients. In pa-
tients without a previous diagnosis of di-
abetes, elevated BG concentrations may
be due to stress hyperglycemia, a condi-
tion that can be established by a review of
prior medical records or measurement of
A1C. A1C values of 6.5–7.0% suggest
that diabetes preceded hospitalization
(87).
Hypoglycemia is deﬁned as any BG
level70mg/dl(3.9mmol/l)(88).This
is the standard deﬁnition in outpatients
and correlates with the initial threshold
for the release of counterregulatory hor-
mones (89). Severe hypoglycemia in hos-
pitalized patients has been deﬁned by
many clinicians as 40 mg/dl (2.2
mmol/l),althoughthisvalueislowerthan
the approximate 50 mg/dl (2.8 mmol/l)
level at which cognitive impairment be-
gins in normal individuals (89–91). As
with hyperglycemia, hypoglycemia among
inpatients is also associated with adverse
short-term and long-term outcomes.
Earlyrecognitionandtreatmentofmildto
moderatehypoglycemia(40and69mg/dl
[2.2 and 3.8 mmol/l], respectively) can
preventdeteriorationtoamoresevereep-
Consensus Statement
1122 DIABETES CARE, VOLUME 32, NUMBER 6, JUNE 2009isode with potential adverse sequelae
(91,92).
Treatment of hyperglycemia in
critically ill patients
On the basis of the available evidence, in-
sulin infusion should be used to control
hyperglycemiainthemajorityofcritically
illpatientsintheICUsetting,withastart-
ingthresholdofnohigherthan180mg/dl
(10.0 mmol/l). Once IV insulin therapy
has been initiated, the glucose level
should be maintained between 140 and
180mg/dl(7.8and10.0mmol/l).Greater
beneﬁtmayberealizedatthelowerendof
this range. Although strong evidence is
lacking, somewhat lower glucose targets
may be appropriate in selected patients.
Targets 110 mg/dl (6.1 mmol/l), how-
ever, are not recommended. Use of insu-
lin infusion protocols with demonstrated
safety and efﬁcacy, resulting in low rates
of occurrence of hypoglycemia, is highly
recommended.
Treatment of hyperglycemia in
noncritically ill patients
With no prospective, RCT data for estab-
lishing speciﬁc guidelines in noncritically
ill patients, our recommendations are
based on clinical experience and judg-
ment. For the majority of noncritically ill
patientstreatedwithinsulin,premealglu-
cose targets should generally be 140
mg/dl (7.8 mmol/l) in conjunction
with random BG values 180 mg/dl
(10.0 mmol/l), as long as these targets
can be safely achieved. For avoidance of
hypoglycemia, consideration should be
given to reassessing the insulin regimen if
BG levels decline below 100 mg/dl (5.6
mmol/l). Modiﬁcation of the regimen is
necessary when BG values are 70 mg/dl
(3.9 mmol/l), unless the event is easily
explained by other factors (such as a
missed meal).
Occasional clinically stable patients
withapriorhistoryofsuccessfultightgly-
cemic control in the outpatient setting
may be maintained with a glucose range
below the aforementioned cut points. In
contrast,higherglucoserangesmaybeac-
ceptableinterminallyillpatientsorinpa-
tients with severe comorbidities, as well
as in those in patient-care settings where
frequent glucose monitoring or close
nursing supervision is not feasible.
We emphasize that clinical judgment
in combination with ongoing assessment
of the patient’s clinical status, including
changes in the trajectory of glucose mea-
sures, the severity of illness, the nutri-
tional status, or the concurrent use of
medications that might affect glucose lev-
els (for example, corticosteroids or oct-
reotide), must be incorporated into the
day-to-day decisions regarding insulin
dosing (93,94).
Inpatient glucose metrics
Hospitalsattemptingtoimprovethequal-
ity of their glycemic control and clinical
investigators who analyze glycemic man-
agement require standardized glucose
measures for assessment of baseline per-
formance and the effect of any interven-
tion (11). Several methods have been
proposed for determining the adequacy
of glycemic control across a hospital or
unit. A recent study indicated that a sim-
ple measure of mean BG (39) provides
information similar to that from more
complex metrics (hyperglycemic index,
time-averaged glucose) (14,48). The “pa-
tient-day” unit of measure is another
proposed metric of hospital glucose data,
especially when there is substantial vari-
ability in the duration of hospital stay
(95). The patient-day metric may yield a
more accurate assessment of the fre-
quency of hypoglycemia and severe hyper-
glycemic events, providing an approach
for obtaining measures of performance
for clinical investigation (95).
The absolute deﬁnition of high-
quality BG control has not been deter-
mined. Of course, one should aim for the
highest percentage of patients within a
prespeciﬁed BG target range. The oppo-
site holds true for hypoglycemia. What is
reasonable for a hospital to achieve and
with what consistency have not been
studied, and information regarding best
practices in this area is needed.
QUESTION 3: WHAT
TREATMENT OPTIONS ARE
AVAILABLE FOR
ACHIEVING OPTIMAL
GLYCEMIC TARGETS
SAFELY AND EFFECTIVELY
IN SPECIFIC CLINICAL
SITUATIONS?— Inthehospitalset-
ting, insulin therapy is the preferred meth-
od for achieving glycemic control in most
clinical situations (8). In the ICU, IV infu-
sionisthepreferredrouteofinsulinadmin-
istration. Outside of critical care units,
subcutaneous administration of insulin
is used much more frequently. Orally ad-
ministered agents have a limited role in
the inpatient setting.
IV insulin infusions
In the critical care setting, continuous IV
insulin infusion has been shown to be the
most effective method for achieving spe-
ciﬁc glycemic targets (8). Because of the
very short half-life of circulating insulin,
IV delivery allows rapid dosing adjust-
ments to address alterations in the status
of patients.
IV insulin therapy is ideally adminis-
tered by means of validated written or
computerized protocols that allow for
predeﬁned adjustments in the insulin in-
fusionratebasedonglycemicﬂuctuations
and insulin dose. An extensive review of
the merits and deﬁciencies of published
protocols is beyond the intent of this
statement,andreadersarereferredtosev-
eral available reports and reviews (96–
101). Continued education of staff in
conjunction with periodic ongoing
review of patient data is critical for suc-
cessful implementation of any insulin
protocol (97–101).
Patients who receive IV insulin infu-
sions will usually require transition to
subcutaneously administered insulin
when they begin eating regular meals or
are transferred to lower-intensity care.
Typically,apercentage(usually75–80%)
of the total daily IV infusion dose is
proportionately divided into basal and
prandial components (see subsequent
material). Importantly, subcutaneously
administeredinsulinmustbegiven1–4h
before discontinuation of IV insulin ther-
apy in order to prevent hyperglycemia
(102). Despite these recommendations, a
safe and effective transition regimen has
not been substantiated.
Subcutaneously administered insulin
Scheduled subcutaneous administration
of insulin is the preferred method for
achieving and maintaining glucose con-
trol in non-ICU patients with diabetes or
stress hyperglycemia. The recommended
components of inpatient subcutaneous
insulinregimensareabasal,anutritional,
and a supplemental (correction) element
(8,103). Each component can be met by
one of several available insulin products,
depending on the particular hospital sit-
uation. Readers are referred to several
recent publications and reviews that de-
scribecurrentlyavailableinsulinprepara-
tions and protocols (101–106).
A topic that deserves particular atten-
tion is the persistent overuse of what has
beenbrandedasslidingscaleinsulin(SSI)
for management of hyperglycemia. The
term “correction insulin,” which refers to
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acting insulin in conjunction with sched-
uledinsulindosestotreatBGlevelsabove
desired targets, is preferred (8). Pro-
longed therapy with SSI as the sole regi-
men is ineffective in the majority of
patients (and potentially dangerous in
those with type 1 diabetes) (106–112).
Noninsulin agents
Noninsulin agents are inappropriate in
most hospitalized patients. Continued
use of such agents may be appropriate in
selected stable patients who are expected
to consume meals at regular intervals.
Caution must be exercised with use of
metformin because of the potential devel-
opment of a contraindication during the
hospitalization, such as renal insufﬁ-
ciency, unstable hemodynamic status, or
need for imaging studies with radiocon-
trast dye (8,113). Injectable noninsulin
therapies such as exenatide and pramlint-
ide have limitations similar to those with
orally administered agents in the hospital
setting.
Speciﬁc clinical situations
Patients using an insulin pump. Pa-
tients who use continuous subcutaneous
insulin infusion (pump) therapy in the
outpatient setting can be candidates for
diabetes self-management in the hospital,
provided they have the mental and phys-
icalcapacitytodoso(8,103,114,115).Of
importance,nursingpersonnelmustdoc-
ument basal rates and bolus doses on a
regularbasis(atleastdaily).Theavailabil-
ity of hospital personnel with expertise in
continuous subcutaneous insulin infu-
sion therapy is essential (115).
Patients receiving enteral nutrition.
Hyperglycemia is a common side effect
of inpatient enteral nutrition therapy
(116,117). A recent study, in which a
combination of basal insulin and correc-
tion insulin was used, achieved a mean
glucose value of 160 mg/dl (8.9 mmol/l).
Similarresultswereachievedinthegroup
randomized to receive SSI only; however,
48% of patients required the addition of
intermediate-acting insulin to achieve
glycemic targets (109).
Patients receiving parenteral nutrition.
The high glucose load in standard paren-
teralnutritionfrequentlyresultsinhyper-
glycemia, which is associated with a
higher incidence of complications and
mortality in critically ill patients in the
ICU (118). Insulin therapy is highly rec-
ommended, with glucose targets as de-
ﬁned previously on the basis of the
severity of illness.
Patients receiving glucocorticoid therapy.
Hyperglycemia is a common complica-
tion of corticosteroid therapy (93). Sev-
eral approaches have been proposed for
treatment of this condition, but no pub-
lished protocols or studies have investi-
gated the efﬁcacy of these approaches. A
reasonable approach is to institute glu-
cose monitoring for at least 48 h in all
patients receiving high-dose glucocorti-
coid therapy and to initiate insulin ther-
apy as appropriate (94). In patients who
are already being treated for hyperglyce-
mia, early adjustment of insulin doses is
recommended (119). Importantly, dur-
ing corticosteroid tapers, insulin dosing
should be proactively adjusted to avoid
hypoglycemia.
QUESTION 4: DOES
INPATIENT MANAGEMENT
OF HYPERGLYCEMIA
REPRESENT A SAFETY
CONCERN?— Overtreatment and
undertreatment of hyperglycemia repre-
sent major safety issues in hospitalized
patients with and without diabetes
(90,120,121).Fearofhypoglycemia,clin-
ical inertia, and medical errors are major
barriers to achieving optimal blood glu-
cose control (90,122–131). In most clinical
situations, safe and reasonable glycemic
control can be achieved with appropri-
ate use of insulin, adjusted according to
results of bedside glucose monitoring
(102,106,109).
Clinical situations that increase the
risk for hypoglycemia and hyperglycemia
in the hospital include the following:
1. Changes in caloric or carbohydrate
intake (“nothing by mouth” status,
enteral nutrition, or parenteral nu-
trition) (94,128)
2. Change in clinical status or medica-
tions (for example, corticosteroids or
vasopressors) (93,98)
3. Failureofthecliniciantomakeadjust-
ments to glycemic therapy based on
daily BG patterns (102,128)
4. Prolonged use of SSI as monotherapy
(107,108)
5. Poor coordination of BG testing and
administration of insulin with meals
(121,129)
6. Poor communication during times of
patienttransfertodifferentcareteams
(120,121)
7. Use of long-acting sulfonylureas in el-
derly patients and those with kidney
or liver insufﬁciency
8. Errors in order writing and transcrip-
tion (102,120)
Hypoglycemiaisamajorsafetyconcern
with use of insulin and insulin secreta-
gogues. Hypoglycemia can occur sponta-
neously in patients with sepsis (130) or
in patients who receive certain medica-
tions, including quinolone antibiotics
and -adrenergic agonists. Although not
all hypoglycemic episodes are avoidable,
the use of nurse-driven hypoglycemia
treatment protocols that prompt early
therapy for any BG levels 70 mg/dl
(3.9 mmol/l) can prevent deterioration
of potentially mild events—for example,
BG values of 60–69 mg/dl (3.3–3.8
mmol/l)—to more severe events—for ex-
ample, BG concentrations 40 mg/dl
(2.2 mmol/l) (88,90–92,98,131). Par-
ticular attention is required in high-risk
patients, including those with malnutri-
tion; advanced age; a history of severe
hypoglycemia (88,132); or autonomic,
kidney, liver, or cardiac failure.
Clinical inertia can be deﬁned as not
adjusting glycemic therapy in response to
persistently abnormal results on BG de-
termination(123).Often,thereisalackof
ownershipfordiabetesmanagement,par-
ticularly in hospitalized patients admit-
ted with a primary diagnosis other than
diabetes (128). This inaction may be
due in part to insufﬁcient knowledge or
conﬁdence in diabetes management
(123,133).Improvementsincarecanbe
achieved by ongoing education and
training (134,135).
Insulin errors
Insulin has consistently been designated
as a high-alert medication because of the
risk of harm that can accompany errors
in prescribing, transcribing, or dosing
(136).Thetruefrequencyofsucherrorsis
unknown because the available data
sources depend on voluntary reporting of
errors (102,137) and mechanisms for
real-timeroot-causeanalysisarenotavail-
able in most hospitals.
BG monitoring
Bedside BG monitoring with use of point-
of-care (POC) glucose meters is per-
formed before meals and at bedtime in
most inpatients who are eating usual
meals. It is important to avoid routine
use of correction insulin at bedtime. In
patients who are receiving continuous
enteral or parenteral nutrition, glucose
Consensus Statement
1124 DIABETES CARE, VOLUME 32, NUMBER 6, JUNE 2009monitoring is optimally performed every
4–6 h. In patients who are receiving cy-
cled enteral nutrition or parenteral nutri-
tion, the schedule for glucose monitoring
can be individualized but should be fre-
quent enough to detect hyperglycemia
during feedings and the risk of hypogly-
cemia when feedings are interrupted
(109,112). More frequent BG testing,
ranging from every 30 min to every 2 h, is
required for patients receiving IV insulin
infusions.
Glucose meters
Safe and rational glycemic management
relies on the accuracy of BG measure-
ments performed with use of POC glu-
cose meters, which have several impor-
tant limitations. Although the U.S. Food
and Drug Administration allows a 20%
error for glucose meters, questions have
been raised about the appropriateness of
this criterion (138). Glucose measure-
ments differ signiﬁcantly between plasma
and whole blood, terms that are often
used interchangeably and can lead to
misinterpretation. Most commercially
available capillary glucose meters intro-
duce a correction factor of 1.12 to re-
port a “plasma adjusted” value (139).
Signiﬁcant discrepancies among cap-
illary, venous, and arterial plasma sam-
ples have been observed in patients with
low or high hemoglobin concentrations,
hypoperfusion, or the presence of inter-
fering substances (139,140). Analytical
variability has been described with sev-
eral POC glucose meters (141). Any glu-
cose result that does not correlate with
thepatient’sclinicalstatusshouldbecon-
ﬁrmed through conventional laboratory
sampling of plasma glucose.
Although laboratory measurement of
plasma glucose has less variability and in-
terference, multiple daily phlebotomies
are not practical. Moreover, the use of in-
dwelling lines as the sampling source
poses risks for infection. Studies per-
formed with use of continuous interstitial
glucose-monitoringsystemsinthecritical
care setting (142,143) currently are lim-
ited by the lack of reliability of BG mea-
surements in the hypoglycemic range as
well as by cost.
QUESTION 5: WHAT
SYSTEMS NEED TO BE IN
PLACE TO ACHIEVE THESE
RECOMMENDATIONS?— The
complexityofinpatientglycemicmanage-
mentnecessitatesasystemsapproachthat
facilitates safe practices and reduces the
risk for errors (120,121). Systems that fa-
cilitate the appropriate use of scheduled
insulin therapy, with institutional sup-
port for inpatient personnel who are
knowledgeable in glycemic management,
are essential for achieving safe and rea-
sonable levels of glycemic control in hos-
pitalized patients. Readers are referred to
the 2006 ACE/ADA consensus statement,
which outlines the systems that must be
in place to promote effective glycemic
managementinthehospital(11).Someof
these recommendations are reviewed
brieﬂy in the following paragraphs.
The success of any glycemic manage-
ment program depends on the ability to
obtainﬁnancialsupportfromhospitalad-
ministrators, who should be made aware
of the potential for cost savings with re-
ductions in morbidity, durations of hos-
pital stay, and need for readmission. This
supportisnecessaryforcoveringthecosts
of staff education, equipment, and per-
sonnel to oversee an inpatient diabetes
management program (144).
The creation of a multidisciplinary
steeringcommitteeguidedbylocaldiabe-
tes experts can establish reasonable and
achievable glycemic management goals
with use of protocols and order sets (90).
Preprintedordersetsorcomputerizedor-
dering systems with adequate technical
supportareusefultoolsforfacilitatingap-
propriate glycemic therapy (8,11,145).
These tools can advance orders that con-
tain contingencies that promote patient
safety, such as withholding prandial in-
sulin if a patient will not eat (102). Proto-
cols need to be reviewed periodically and
revised in accordance with available
evidence.
Inpatient providers often have insuf-
ﬁcientknowledgeaboutthemanyaspects
ofinpatientdiabetescare(133).Thus,ed-
ucation of personnel is essential, espe-
cially early during the implementation
phase (101,127). Formal communication
among various disciplines and services
helpstogarnersupportfromhospitalper-
sonnelfornewpracticesandprotocols,as
well as providing a venue for identifying
concerns.
Many hospitals are challenged by
poor coordination of meal delivery and
prandial insulin administration (130), as
well as variability in the carbohydrate
contentofmeals(94).Ensuringappropri-
ate administration of insulin with respect
to meals despite variations in food de-
livery necessitates coordination between
dietary and nursing services (122). A sys-
tems approach can also promote the co-
ordination of glucose monitoring, insulin
administration, and meal delivery, partic-
ularlyduringchangeofshiftsandtimesof
patient transfer (121,122).
Electronic health records and com-
puterized physician order entry systems
have the potential to improve the sharing
of information, including POC glucose
results and associated medication admin-
istration—whichcancontributetothere-
duction of medical errors. These systems
can also provide access to algorithms,
protocols,anddecisionsupporttoolsthat
can help guide therapy (146,147).
QUESTION 6: IS
TREATMENT OF INPATIENT
HYPERGLYCEMIA COST-
EFFECTIVE?— A program of inpa-
tient glycemic control with prespeciﬁed
glycemictargetswillhaveassociatedcosts
attributable to an increase in time needed
from physicians, nurses, pharmacists,
and other services. These costs are best
viewed as short-term investments that ul-
timately provide long-term cost savings
because of improved clinical outcomes,
withobserveddecreasesinLOS,inpatient
complications, and need for rehospital-
ization (148–155).
Pharmacoeconomic analyses have
examined the cost-effectiveness of im-
proved glycemic control in the hospital
setting (148,149). In the Portland Dia-
betic Project, a 17-year prospective non-
randomized study of 4,864 patients with
diabetes who underwent open-heart
surgical procedures, institution of con-
tinuous IV insulin therapy to achieve
predetermined target BG levels reduced
the incidence of deep sternal wound in-
fections by 66%, resulting in a total net
savings to the hospital of 4,638 USD per
patient (148). In another study, intensive
glycemiccontrolin1,600patientstreated
in a medical ICU was associated with a
total cost savings of 1,580 USD per pa-
tient (149). Van den Berghe et al. (150)
reported cost savings of 3,476 USD per
patient by strict normalization of BG lev-
els with use of a post hoc health care
resource utilization analysis of their ran-
domized mechanically ventilated surgical
ICUpatients.Inaretrospectiveanalysisof
patients undergoing coronary artery by-
pass grafting, each 50 mg/dl (2.8 mmol/l)
increase in BG values on the day of and
after the surgical procedure was associ-
ated with an increase in hospital cost of
1,769 USD and an increase in duration of
hospital stay of 0.76 days (151). In a ter-
tiary care trauma center, implementation
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duce the monthly mean BG level by 26
mg/dl (1.4 mmol/l) (177–151 mg/dl
[9.8–8.4 mmol/l]) resulted in signiﬁcant
reductions in LOS (0.26 days) in associa-
tion with estimated hospital savings of
more than two million USD per year
(152). In another study, implementation
of a subcutaneous insulin protocol for
treatment of patients with hyperglycemia
intheemergencydepartmentresultedina
subsequent reduction of hospital stay by
1.5 days (153).
The use of an intensiﬁed inpatient
protocol by a diabetes management team
resulted in correct coding and treatment
of patients with previously unrecognized
hyperglycemia. The LOS was reduced for
both primary and secondary diagnoses of
diabetes, and readmission rates declined
(154). In a different study, the use of dia-
betes team consultation resulted in a 56%
reduction in LOS and a cost reduction of
2,353 USD per patient (155).
Thus, intensive glycemic control pro-
grams have reported substantial cost sav-
ings,primarilyattributabletodecreasesin
laboratory, pharmacy, and radiology
costs; fewer inpatient complications; de-
creased ventilator days; and reductions
in ICU and hospital LOS. These reports
demonstrate that optimization of inpa-
tient glycemic management not only is
effective in reducing morbidity and mor-
tality but also is cost-effective. The busi-
ness case for hospital support of glycemic
management programs is based on op-
portunities for improving the accuracy of
documentation and coding for diabetes-
related diagnoses. The case for revenue
generationthroughbillingforclinicalser-
vicesisbasedonopportunitiestoincrease
the provision of glycemic management
services in the hospital. It is imperative to
involvehospitaladministrationinprovid-
ing the necessary ﬁnancial support for in-
patient glycemic management programs
that will ultimately result in cost savings
in conjunction with improved patient
outcomes.
QUESTION 7: WHAT ARE
THE OPTIMAL STRATEGIES
FOR TRANSITION TO
OUTPATIENT CARE?— Prepara-
tionfortransitiontotheoutpatientsetting
is an important goal of inpatient diabetes
managementandbeginswiththehospital
admission. This entails a fundamental
shift in responsibility from a situation in
which hospital personnel provide the di-
abetes care to one in which the patient is
capable of self-management. Successful
coordination of this transition requires a
team approach that may involve physi-
cians, nurses, medical assistants, dieti-
tians, case managers, and social workers
(8). Hospitals with certiﬁed diabetes edu-
cators beneﬁt from their expertise during
the discharge process.
Admission assessment obtains infor-
mation regarding any prior history of di-
abetesorhyperglycemia,itsmanagement,
and the level of glycemic control. Early
assessment of a patient’s cognitive abili-
ties, literacy level, visual acuity, dexterity,
cultural context, and ﬁnancial resources
for acquiring outpatient diabetic supplies
allows sufﬁcient time to prepare the pa-
tient and address problem areas.
Hospitalizationprovidesauniqueop-
portunity for addressing a patient’s edu-
cation in diabetes self-management (3).
Because the mean hospital LOS is usually
5days(2)andthecapacitytolearnnew
material may be limited during acute ill-
ness, diabetes-related education is fre-
quently limited to an inventory of basic
“survival skills.”
It is recommended that the follow-
ing areas be reviewed and addressed be-
fore the patient is discharged from the
hospital (8):
● Level of understanding related to the
diagnosis of diabetes
● Self-monitoring of BG and explanation
of home BG goals
● Deﬁnition, recognition, treatment, and
prevention of hyperglycemia and
hypoglycemia
● Identiﬁcation of health care provider
who will be responsible for diabetes
care after discharge
● Informationonconsistenteatingpatterns
● When and how to take BG-lowering
medications, including administration
of insulin (if the patient is receiving in-
sulin for ongoing management at home)
● Sick day management
● Proper use and disposal of needles and
syringes
Medication errors and adverse drug
events have been linked to poor commu-
nication of instructions to the patient at
the time of discharge (156,157). This is
particularly true for insulin regimens,
which are inherently more complex. Be-
cause the day of discharge is not always
conducive to retention of verbal instruc-
tions (158), clearly written instructions
provide a reference for patients and their
outpatient providers, and they provide a
format for medication reconciliation be-
tween inpatient and outpatient settings.
In one recent study, an insulin-speciﬁc
discharge instruction form provided
greater clarity and more consistent direc-
tions for insulin dosing and self-testing of
BG in comparison with a generic hospital
discharge form (159).
Anoutpatientfollow-upvisitwiththe
primary care provider, endocrinologist,
or diabetes educator within 1 month after
discharge from the hospital is advised for
all patients having hyperglycemia in the
hospital (8). Clear communication with
outpatient providers either directly or by
means of hospital discharge summaries
facilitates safe transitions to outpatient
care. Providing information regarding the
cause or the plan for determining the
causeofhyperglycemia,relatedcomplica-
tions and comorbidities, and recom-
mended treatments can assist outpatient
providers as they assume ongoing care.
QUESTION 8: WHAT ARE
AREAS FOR FUTURE
RESEARCH?— The following are se-
lected research topics and questions pro-
posed for guiding the management of
patients with hyperglycemia in various
hospital settings.
Stress hyperglycemia
● What are the underlying mechanisms?
● What abnormalities lead to variability
in insulin resistance observed in some
critically ill patients?
● What therapeutic modalities, in addi-
tion to glycemic control, would im-
prove outcomes in critically ill patients
with hyperglycemia?
● Arethereoptimalandsafeglycemictar-
gets speciﬁc to certain populations of
critically ill patients?
Severe hypoglycemia
● What is the proﬁle of inpatients at
greatest risk for severe hypoglycemia?
● What are the short-term and long-term
outcomes of patients experiencing se-
vere hypoglycemia?
● What are the true costs of inpatient
hypoglycemia?
Glycemic targets on general medical
and surgical wards
● Whatareoptimalandsafeglycemictar-
getsinnoncriticallyillpatientsonmed-
ical and surgical wards? Recommended
end points for an RCT include rates of
hypoglycemia, hospital-acquired infec-
Consensus Statement
1126 DIABETES CARE, VOLUME 32, NUMBER 6, JUNE 2009tions, other in-hospital complications,
LOS, and readmission.
Glycemic variability
● Whatistheeffectofglycemicvariability
and the rate of change in glycemia on
short-term and long-term outcomes,
both in ICU and non-ICU settings?
Hospital systems and safety
● What hospital systems and safety mea-
sures are important for improving gly-
cemic control and patient outcomes?
● What teams and support systems are
requiredforsafeandeffectivetransition
of patients to the outpatient setting?
Insulin treatment and monitoring
instruments
● Whataresafeandeffectivestrategiesfor
inpatient use of insulin and insulin
analogues?
● What is the role of continuous glucose-
monitoring systems in inpatient settings?
Pediatric inpatient populations
● What are the optimal and safe glycemic
targets in noncritically ill hospitalized
children?
SUMMARY OF
RECOMMENDATIONS
I. Critically ill patients
● Insulin therapy should be initiated for
treatment of persistent hyperglycemia,
startingatathresholdofnogreaterthan
180 mg/dl (10.0 mmol/l).
● Once insulin therapy has been started,
a glucose range of 140–180 mg/dl
(7.8–10.0mmol/l)isrecommendedfor
the majority of critically ill patients.
● Intravenous insulin infusions are the
preferred method for achieving and
maintaining glycemic control in criti-
cally ill patients.
● Validated insulin infusion protocols
with demonstrated safety and efﬁcacy,
and with low rates of occurrence of hy-
poglycemia, are recommended.
● With IV insulin therapy, frequent glu-
cose monitoring is essential to mini-
mize the occurrence of hypoglycemia
and to achieve optimal glucose control.
II. Noncritically ill patients
● For the majority of noncritically ill pa-
tients treated with insulin, the premeal
BG target should generally be 140
mg/dl (7.8 mmol/l) in conjunction
with random BG values 180 mg/dl
(10.0mmol/l),providedthesetargets
can be safely achieved.
● More stringent targets may be appro-
priate in stable patients with previous
tight glycemic control.
● Less stringent targets may be appropri-
ate in terminally ill patients or in pa-
tients with severe comorbidities.
● Scheduled subcutaneous administra-
tion of insulin, with basal, nutritional,
and correction components, is the pre-
ferred method for achieving and main-
taining glucose control.
● Prolonged therapy with SSI as the sole
regimen is discouraged.
● Noninsulin antihyperglycemic agents
are not appropriate in most hospital-
ized patients who require therapy for
hyperglycemia.
● Clinical judgment and ongoing assess-
ment of clinical status must be incorpo-
ratedintoday-to-daydecisionsregarding
treatment of hyperglycemia.
III. Safety issues
● Overtreatment and undertreatment of
hyperglycemia represent major safety
concerns.
● Education of hospital personnel is es-
sential in engaging the support of those
involved in the care of inpatients with
hyperglycemia.
● Caution is required in interpreting re-
sults of POC glucose meters in patients
with anemia, polycythemia, hypoper-
fusion, or use of some medications.
● Buy-in and ﬁnancial support from hos-
pital administration are required for
promoting a rational systems approach
to inpatient glycemic management.
IV. Cost
● Appropriate inpatient management of
hyperglycemia is cost-effective.
V. Discharge planning
● Preparation for transition to the outpa-
tient setting should begin at the time of
hospital admission.
● Discharge planning, patient education,
and clear communication with outpa-
tient providers are critical for ensuring
a safe and successful transition to out-
patient glycemic management.
VI. Needed research
● A selected number of research ques-
tions and topics for guiding the man-
agement of inpatient hyperglycemia in
various hospital settings are proposed.
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